Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin for Steroid-Refractory GVHD
NCT02203578Terminated
- Sponsor
- Rutgers University
- Start
- Nov 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of romidepsin in graft-versus-host disease (GVHD), sponsored by Rutgers University. Primary endpoints: Incidence of Acute Graft-versus-Host Disease at 28 days and Incidence of Chronic Graft-versus-Host Disease at 12 months. Started Nov 2014; status: terminated.
02
Drugs
romidepsin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02203578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203578.